Abstract
The present study was undertaken to examine whether the mechanism of action of typical and atypical antipsychotics is related in their ability to regulate key phosphorylating enzyme of adenylyl cyclase-cAMP pathway, i.e., protein kinase A (PKA). For this purpose, regulatory (R) and catalytic (Cat) activities of PKA and expression of various isoforms of regulatory and catalytic subunits were examined in rat brain after single or chronic (21-day) treatment with haloperidol (HAL, 1 mg/kg) or clozapine (CLOZ, 20 mg/kg). It was observed that chronic but not acute treatment of CLOZ significantly decreased [3H]cAMP binding to the regulatory subunit of PKA as well as catalytic activity of PKA in particulate and cytosol fractions of the rat cortex, hippocampus, and striatum. In these fractions, CLOZ significantly decreased protein levels of selective RIIα-, RIIβ-, and Catβ-subunit isoforms of PKA. These decreases were accompanied by decreases in their respective mRNA expression. In contrast, chronic but not acute treatment of HAL significantly increased [3H]cAMP binding and the catalytic activity of PKA in particulate and cytosol fractions of only the striatum brain area. In addition, chronic treatment of HAL significantly increased mRNA and protein levels of RIIα- and RIIβ-subunit isoforms in the striatum. None of the antipsychotics caused any change in the expression of the Catα-, RIα-, or RIβ-subunit isoform. These results, thus, suggest that HAL and CLOZ differentially regulate PKA catalytic and regulatory activities and the expression of selective catalytic and regulatory subunit isoforms of PKA, which may be associated with their mechanisms of action.
Footnotes
-
This study was supported by Grant KO1 MH01836 from the National Institute of Mental Health and Young Investigator Award from the American Foundation of Suicide Prevention (to Y.D.) and Grant RO1-MH56528 from the National Institute of Mental Health (to G.N.P.).
- Abbreviations:
- Cat
- catalytic
- CLOZ
- clozapine
- HAL
- haloperidol
- PKA
- protein kinase A
- PKC
- protein kinase C
- R
- regulatory
- ECL
- enhanced chemiluminescence
- EPS
- extrapyramidal side effects
- TD
- tardive dyskinesia
- RT-PCR
- reverse transcriptase-polymerase chain reaction
- AEBSF
- 4-(2-aminoethyl)-benzenesulfonyl fluoride
- bp
- base pair(s)
- Received October 17, 2001.
- Accepted December 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|